76 related articles for article (PubMed ID: 8121779)
21. MR imaging of the liver with Resovist: safety, efficacy, and pharmacodynamic properties.
Kopp AF; Laniado M; Dammann F; Stern W; Grönewäller E; Balzer T; Schimpfky C; Claussen CD
Radiology; 1997 Sep; 204(3):749-56. PubMed ID: 9280254
[TBL] [Abstract][Full Text] [Related]
22. MR contrast material for vascular enhancement: value of superparamagnetic iron oxide.
Mayo-Smith WW; Saini S; Slater G; Kaufman JA; Sharma P; Hahn PF
AJR Am J Roentgenol; 1996 Jan; 166(1):73-7. PubMed ID: 8571910
[TBL] [Abstract][Full Text] [Related]
23. [Superparamagnetic iron particles. The clinical results in the MR diagnosis of liver metastases].
Ham B; Reichel M; Vogl T; Taupitz M; Wolf KJ
Rofo; 1994 Jan; 160(1):52-8. PubMed ID: 8305693
[TBL] [Abstract][Full Text] [Related]
24. Superparamagnetic iron oxide: clinical time-response study.
Gandon Y; Heautot JF; Brunet F; Guyader D; Deugnier Y; Carsin M
Eur J Radiol; 1991; 12(3):195-200. PubMed ID: 1649755
[TBL] [Abstract][Full Text] [Related]
25. Double contrast MR imaging of hepatocellular carcinoma evaluating lesion detection and conspicuity.
Akinci D; Oto A; Besim A; Akhan O; Abbasoglu O; Batman F; Eryilmaz M
Acad Radiol; 2002 Aug; 9 Suppl 2():S466-7. PubMed ID: 12188310
[No Abstract] [Full Text] [Related]
26. SPIO-MRI in the detection of hepatocellular carcinoma.
Araki T
J Gastroenterol; 2000; 35(11):874-6. PubMed ID: 11085500
[No Abstract] [Full Text] [Related]
27. [The value of the liver-specific superparamagnetic contrast medium AMI-25 for the detection and differential diagnosis of primary liver tumors versus metastases].
Vogl TJ; Hammerstingl R; Pegios W; Hamm B; Eibl-Eibesfeldt A; Woessmer B; Lissner J; Felix R
Rofo; 1994 Apr; 160(4):319-28. PubMed ID: 8161744
[TBL] [Abstract][Full Text] [Related]
28. [Obsolete methods in examination of the liver with MRI].
Schadmand-Fischer S
Rofo; 1998 Dec; 169(6):679-80. PubMed ID: 9930229
[No Abstract] [Full Text] [Related]
29. [Evaluation of AMI-25 enhanced MR imaging and enhanced helical CT for liver tumors].
Yamamoto K; Shimizu T; Hiraishi K; Ashina K; Sagami A; Aratake K; Maeda H; Matsui R; Kawai T; Narabayashi I
Nihon Igaku Hoshasen Gakkai Zasshi; 1995 Jan; 55(1):1-6. PubMed ID: 7899060
[TBL] [Abstract][Full Text] [Related]
30. Preparation and biomedical application of a non-polymer coated superparamagnetic nanoparticle.
Du L; Chen J; Qi Y; Li D; Yuan C; Lin MC; Yew DT; Kung HF; Yu JC; Lai L
Int J Nanomedicine; 2007; 2(4):805-12. PubMed ID: 18203447
[TBL] [Abstract][Full Text] [Related]
31. Results of a multicenter phase II clinical trial with a susceptibility contrast medium for magnetic resonance imaging of the liver.
Balzer T; Carter EC; Shamsi K; Niendorf HP
Acad Radiol; 1996 Aug; 3 Suppl 2():S417-9. PubMed ID: 8796619
[No Abstract] [Full Text] [Related]
32. Real enhancement or merely increased contrast?
Chen JH
AJR Am J Roentgenol; 1997 Jan; 168(1):279-80. PubMed ID: 8976963
[No Abstract] [Full Text] [Related]
33. Pharmacokinetic modeling of phagocytic activity of the liver using superparamagnetic iron oxide nanoparticles in dynamic MR imaging.
Na JB; Suh JS; Huh YM; Kim SJ; Kim SH; Cha SH; Lee SH
Yonsei Med J; 2003 Jun; 44(3):429-37. PubMed ID: 12833580
[TBL] [Abstract][Full Text] [Related]
34. Superparamagnetic iron oxide-enhanced magnetic resonance imaging of experimental liver tumors after mitomycin C administration.
Clement O; Frija G; Chambon C; Schouman-Clayes E
Invest Radiol; 1992 Mar; 27(3):230-5. PubMed ID: 1551774
[TBL] [Abstract][Full Text] [Related]
35. [Focal intrahepatic siderosis, diagnostic pitfall, iatrogenic image].
Arteaga C; Raillat A; Salamand P; Debonne JM; Bonnet D; Martet G; Veuillet MO; Battini-Nouzille A; Briant JF
J Radiol; 1998 Feb; 79(2):157-8. PubMed ID: 9757234
[No Abstract] [Full Text] [Related]
36. [Functional magnetic resonance imaging (MRI) of hepatic ischemia in the rabbit. Contribution of a particulated contrast agent (AMI-25)].
Canet E; Roger T; Chambon C; Delabre C; Baldy C; Revel D
Anat Histol Embryol; 1996 Mar; 25(1):23-9. PubMed ID: 8644929
[TBL] [Abstract][Full Text] [Related]
37. Safety profile of ultrasmall superparamagnetic iron oxide ferumoxtran-10: phase II clinical trial data.
Sharma R; Saini S; Ros PR; Hahn PF; Small WC; de Lange EE; Stillman AE; Edelman RR; Runge VM; Outwater EK; Morris M; Lucas M
J Magn Reson Imaging; 1999 Feb; 9(2):291-4. PubMed ID: 10077027
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic efficacy and safety of MRI of the liver with superparamagnetic iron oxide particles (SH U 555 A).
Kehagias DT; Gouliamos AD; Smyrniotis V; Vlahos LJ
J Magn Reson Imaging; 2001 Nov; 14(5):595-601. PubMed ID: 11747012
[TBL] [Abstract][Full Text] [Related]
39. Safety of ferucarbotran in MR imaging of the liver: a pre- and postexamination questionnaire-based multicenter investigation.
Onishi H; Murakami T; Kim T; Hori M; Hirohashi S; Matsuki M; Narumi Y; Imai Y; Sakurai K; Nakamura H
J Magn Reson Imaging; 2009 Jan; 29(1):106-11. PubMed ID: 19097079
[TBL] [Abstract][Full Text] [Related]
40. Clinical impact of Resovist-enhanced MRI: results of an Italian multicenter trial.
Lencioni R; Bartolozzi C;
Eur Radiol; 2004 Jan; 14 Suppl 1():C10. PubMed ID: 15113061
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
